Trial Profile
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Clofarabine (Primary) ; Granulocyte colony-stimulating factors; Granulocyte colony-stimulating factors; Melphalan; Muromonab CD3; Mycophenolate mofetil; Rituximab; Thiotepa
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms REFLEX
- 30 Dec 2016 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
- 27 Apr 2015 According to a Cellular Biomedicine media release, data from this study will be presented at the 10th Annual World Stem Cells & Regenerative Medicine Congress 2015.